Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195711 · ClinicalTrials.gov registry record
Comparative Validation of "Blinq" and "2WIN" Vision Screeners
A clinical trial, sponsored by Alaska Blind Child Discovery.
- Completed
- Registry status
- 100
- Enrollment target
NCT04195711 is a clinical trial that has completed, run by Alaska Blind Child Discovery. The registered enrollment target is 100 participants.
The verdict
NCT04195711 has completed, sponsored by Alaska Blind Child Discovery.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.
Interventions
- DIAGNOSTIC_TEST objective pediatric vision screen, "blinq,"
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2019-11-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04195711
The ClinicalTrials.gov registry entry for NCT04195711 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaska Blind Child Discovery, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which objective pediatric vision screen, "blinq," is the first listed.
NCT04195711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04195711 about?
NCT04195711 is a clinical study titled "Comparative Validation of "Blinq" and "2WIN" Vision Screeners". After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and ...
What is the current status of trial NCT04195711?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-11-18. Estimated completion is 2019-11-26.
What interventions are being tested in trial NCT04195711?
The interventions under investigation include: objective pediatric vision screen, "blinq," (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04195711?
This trial is sponsored by Alaska Blind Child Discovery, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.